Immunotherapy for acute myelogenous leukaemia - Wikidata - wikimedia - TriplyDB

Immunotherapy for acute myelogenous leukaemia

Immunotherapy for acute myelogenous leukaemia

http://www.wikidata.org/entity/Q36040337

about

Tumor immunology with particular reference to malignant melanoma.Malignancy: Gene Therapy Vaccines in Acute Myeloid Leukemia : A Need for Clinical Evaluation.Active immunotherapy as an adjunct to chemotherapy in the treatment of disseminated malignant melanoma: a pilot study.Immunotherapy using BCG during remission induction and as the sole form of maintenance in acute myeloid leukaemia.Stimulation of autologous blood lymphocytes by malignant lymphoma cells and homogenates.Further evidence of response by leukaemia patients in remission to antigen(s) related to acute myelogenous leukaemia.Immunotherapy for acute myelogenous leukaemia: a controlled clinical study 2 1/2 years after entry of the last patient.Autologous leukemia-specific T-cell-mediated lymphocytotoxicity in patients with acute myelogenous leukemia.Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy.Granuloma formation in patients receiving BCG immunotherapy.Colony-forming ability of marrow from patients receiving immunotherapy during chemotherapy-induced remission in acute myeloid leukaemia Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?Immunotherapy of elderly acute myeloid leukemia: light at the end of a long tunnel?Remission-induction regimens in acute nonlymphocytic leukemia.The treatment of cancer with activated cytotoxic leukocyte subsets.Treatment of acute leukemia in protected environment units.Clinical trials of immunotherapy: present status.Immunotherapy with BCG administered by scarification: standardization of reactions and management of side effects.Future prospects for immunotherapy.Immunotherapy and vaccination against cancer with non-living BCG and cord factor (trehalose-6,6'-dimycolate).Immunological monitoring and immunotherapy in carcinoma of the lung.High-viability lyophilized Bacille Calmette-Guérin vaccine produced by deep-culture technique.Adjuvant immunotherapy of lung cancer with BCG cell wall skeleton (BCG-CWS).New looks in leukemia.Cytotoxic antibody in acute myeloblastic leukaemia during immunotherapy: lack of tumour specificity.HLA linked resistance factors and survival in acute myelogenous leukemia.Immunotherapy and chemoimmunotherapy of malignant disease with BCG and nonviable mycobacterial fractions.Active immunotherapy in acute myelogenous leukaemia and the induction of second and subsequent remissions.Immunotherapy of leukaemias: present status and future prospects.Surface antigens in acute myeloblastic leukaemia: a study using heterologous antisera.Effect of dose, route, and schedule of BCG on antibody titer and survival of murine skin grafts across a weak histocompatibility barrier.The immunotherapy of acute myelogenous leukaemia using intravenous BCG.Inhibition of leukaemia blast cell motility as a test for specific antibody in acute adult myelogenous leukaemia.Influence of orally administered B.C.G. on growth of transplanted rat tumours.Skin reaction and antibody responses in guinea-pigs sensitized to human leukaemia cells or their nuclei in combination with Bacillus Calmette-Guérin.Cell-mediated cytotoxicity as a result of immunotherapy in patients with acute myeloid leukaemia.Factors influencing prognosis in adults with acute myelogenous leukaemia.Intermittent chemotherapy and immunotherapy with BCG in remission maintenance of children with acute lymphocytic leukemia: effects upon immunological function.Vibrio Cholerae neuraminidase susceptible N-acetyl neuraminic acid (sialic acid) levels in human leukaemia.Meningeal leukemia after blastic transformation of chronic myeloid leukemia.

P2860

Q33991120-B7B61E85-21BC-4A94-AB77-B52F91D859E6 Q34278291-0B4889DF-A711-41B0-85D4-07F5E4FD65F8 Q36041590-E9B45B58-7496-4660-9ED9-BF6CC40B4868 Q36043517-9B232943-94DF-4582-89F6-D297FCBBA97E Q36068882-B056BC77-229E-441F-A4EA-6005F9775259 Q36068942-09EB9199-B277-49F1-BAE5-D3BE3AB858D1 Q36068946-6601E56E-4AE2-4127-BC0B-1D78387693DA Q36340009-9C536891-D0FC-4159-B238-980B2F674309 Q36373370-5D01C6A7-3E2F-4025-8A51-B60EEFABC68E Q36600931-89C4A378-E32C-49A2-861A-516BD25229A2 Q36615826-37FAC2F3-95D1-4F2E-9259-3EAC7F490E2F Q38664735-D9BE6FB7-3428-42CA-9FFF-D358FF1FDDA4 Q39205106-42C78B3B-A850-4558-AC9F-2BB9305538BC Q39337855-FE96482A-183C-4A32-8D76-26795D72A531 Q39603743-6D140BE7-F2FA-454B-8FDA-AABEE66532AF Q39682046-7ECF545D-1726-4340-BF2B-320F569C5B5E Q39780007-9E2A800A-8BFA-4382-88C1-C6CE6183F31C Q39780012-A2D0F861-FFEA-4568-86F5-1A7A924EA595 Q39946693-9D55FDC8-3399-4555-B193-5FD5459302B3 Q39952517-20B62389-4BDF-4DB7-94C5-D1D279C7D497 Q40027104-3713C919-98B4-4FAA-A32B-372179138D5D Q40074475-6A243B5E-5975-446D-B407-4D58680D108C Q40229482-AFF8DD60-F5B8-40F7-8DA5-BBA23637CCED Q40305456-2E0E3895-1B26-43BA-B28E-5B29EBCA1F8D Q40480951-191D17B6-E81B-4641-8005-18985CBF87EC Q40488055-A604BDE3-2218-4021-ABC8-6E0E8725D592 Q40516727-D6CDD265-B401-4C07-B684-F078655B7EC7 Q40521351-DFC1BD1D-FFFE-4D79-B604-C4CD6F9D755C Q40561429-23037EE9-C1D5-494D-8336-7E6EE1790AB2 Q40570038-6F2704ED-518E-4EEE-9CF7-6DA46ECF253E Q40749536-5DD18C8F-D055-4E27-A5C0-DBE5399CB21C Q40762893-A976050B-0BE7-415C-B1B9-350DE6D9ABC8 Q40779238-560741E9-CC9E-4385-A12D-130600B4FEF3 Q41452802-1C9EB479-4DC5-42EE-9952-02DFC3AF448C Q41903392-292DE596-5658-4B0C-8870-4F59B73DAAF3 Q42152021-0C04430B-6624-4D61-931D-31287FBC3733 Q42577668-8D9D61AB-48DB-4B9A-8C4C-430D3DB7CAC7 Q43621970-48024743-1271-4046-9732-6D90589E5141 Q44398009-046DBF14-2AB6-4986-936F-C61341D50A6E Q48478869-038995F3-E306-4093-8D0F-5FDB69C1E24F

P2860

Immunotherapy for acute myelogenous leukaemia

http://www.wikidata.org/entity/Q36040337

description

1973 nî lūn-bûn

@nan

1973年の論文

@ja

1973年論文

@yue

1973年論文

@zh-hant

1973年論文

@zh-hk

1973年論文

@zh-mo

1973年論文

@zh-tw

1973年论文

@wuu

1973年论文

@zh

1973年论文

@zh-cn

name

Immunotherapy for acute myelogenous leukaemia

@ast

Immunotherapy for acute myelogenous leukaemia

@en

type

label

Immunotherapy for acute myelogenous leukaemia

@ast

Immunotherapy for acute myelogenous leukaemia

@en

prefLabel

Immunotherapy for acute myelogenous leukaemia

@ast

Immunotherapy for acute myelogenous leukaemia

@en

P1433

Q36040337-911B75C5-8C48-4DD9-A55B-98CB6D42EFFA

P1476

Q36040337-7A38B217-8DC6-44FF-B9D2-E7241074C802

P2093

Q36040337-01F313D9-EB82-4BCE-A783-5EA2E2537C4E

Q36040337-1ACA149A-EEBF-4F0A-B428-9000F7BA50D8

Q36040337-232E3568-53F0-476A-890A-C65CCB52A32D

Q36040337-2AE5B39E-D140-4C63-9C89-344BF758BCF8

Q36040337-89834B88-8853-4901-A02A-4CBFF4EA678A

Q36040337-A33B89F4-9BB2-4C79-9C25-499062580CAD

Q36040337-A59DF85D-1D2A-4240-BB53-A5D89BF204F5

Q36040337-B0607EFD-DA53-4EE2-8350-BF99DFFF4CCC

Q36040337-E25389DC-AC19-4B8F-BBF4-554ED0E7D283

Q36040337-EABF0451-3FFB-4516-8643-84373B90D6D1

P2860

Q36040337-06B11C63-B53D-4EE7-8A7D-0E86F5F9ACFA

Q36040337-0BAF4970-AD25-4251-9AF6-CD3D8C28415D

Q36040337-0FAFE76B-D377-4494-859A-F2450CEDBF14

Q36040337-2FC96021-7A39-43B3-AD67-3865587410BF

Q36040337-32D40E58-9D28-48BB-83DC-E6A193A7E917

Q36040337-55CAE4CF-3CC9-4EBB-8B7A-D84EAE0D15EB

Q36040337-747D1353-D548-488C-BFD8-92FC0E694B6B

Q36040337-808C5A38-1410-4BF5-9E39-20475AB49358

Q36040337-8739595A-9EC5-4AF4-A5D3-A418CE2D1DDB

Q36040337-911996EB-5785-4105-AB77-64CC8C73C912

P2888

Q36040337-74D5BF2D-810B-4691-985B-7E4359A72F59

P304

Q36040337-2C05E4CF-A48C-4518-93FE-79B756E9AC03

P31

Q36040337-FFD41D72-01AB-4B93-8ACB-F92F2662A7D8

P356

Q36040337-FBC42225-0236-41AD-AFA6-265E19FABC19

P407

Q36040337-CC08AB48-1081-4949-82B9-39B20D1984FF

P433

Q36040337-C92E45D8-49B9-4F1A-8706-37F30BDF973E

P478

Q36040337-2AD6913A-D920-4F0A-979F-24E69875CC2E

P577

Q36040337-C2F3645C-7808-47B3-838A-70D7CEB7BCDE

P5875

Q36040337-4EBA20EE-B6FA-486C-BF1D-502306C9719B

P698

Q36040337-355781B9-E7D4-4B9A-89A7-8D67D48C2C54

P921

Q36040337-2FF6B22E-81C2-4BE3-BB3A-2FAD7CA7E501

Q36040337-A531E1AE-787C-46D2-897A-8D59AB73992A

P932

Q36040337-9CE2A263-9894-4C43-A7CA-E31F047BF823

P356

P1433

British Journal of Cancer

P1476

Immunotherapy for acute myelogenous leukaemia

@en

P2093

Alexander P

http://www.w3.org/2001/XMLSchema#string

Bateman CJ

http://www.w3.org/2001/XMLSchema#string

Beard ME

http://www.w3.org/2001/XMLSchema#string

Crowther D

http://www.w3.org/2001/XMLSchema#string

Fairley GH

http://www.w3.org/2001/XMLSchema#string

Lister TA

http://www.w3.org/2001/XMLSchema#string

McElwain TJ

http://www.w3.org/2001/XMLSchema#string

Pike M

http://www.w3.org/2001/XMLSchema#string

Powles RL

http://www.w3.org/2001/XMLSchema#string

Russell J

http://www.w3.org/2001/XMLSchema#string

P2860

Evaluation of survival data and two new rank order statistics arising in its consideration.

Eighty years of immunotherapy: a review of immunological methods used for the treatment of human cancer.

Active immunotherapy of L1210 leukaemia applied after the graft of tumour cells.

Glioblastoma multiforme: a controlled trial to assess the value of specific active immunotherapy in patients treated by radical surgery and radiotherapy.

Response of syngeneic murine lymphomata to immunotherapy in relation to the antigenicity of the tumour.

Serum mediated inhibition of the immunological reactions of the patient to his own tumour: a possible role for circulating antigen.

Combination chemotherapy using L-asparaginase, daunorubicin, and cytosine arabinoside in adults with acute myelogenous leukaemia.

Acute myelocytic leukemia in adults.

Stimulation of lymphocytes by autologous leukaemic cells in acute leukaemia.

Auto-immunization with acute leukemia cells: demonstration of increased lymphocyte responsiveness.

P2888

P304

365-376

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.1973.162

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P577

1973-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

18895160

http://www.w3.org/2001/XMLSchema#string

P698

4271320

http://www.w3.org/2001/XMLSchema#string

P921

P932

2008928

http://www.w3.org/2001/XMLSchema#string